Poel-van de Luytgaarde, S.C.P.A.M. van der

patient evi 1 expression mutation evi 1 expression 1-evi leukemia group cebpadm mds 1-evi myeloid leukemia cebpasm cebpa myeloid mds 1-evi expression blood aml patients table analysis survival value figure sample outcome probe abnormality cebpa mutations prognostic karyotype study dasatinib cebpawt cytogenetic mds 1 expression number signature marrow correlation transcript cohort 214-abl cebpasm aml germline fication genotype mds 1 level abl 1 treatment kinase cebpadm aml bone marrow samples j clin oncol erasmus university classi protein analyses expression levels volume cn-aml groups i february polymerase chain reaction netherland cebpa germline mutations c-terminal count result amlsg signi classi fication fi ndings cell transplantation chemotherapy flt 3 gene cancer nding prognostic value intermediate-risk flt 3itd